Merck & Co., Inc. $MRK Stock: 1834 Investment Advisors Co. Decreases Position

Key Points

• 1834 Investment Advisors reduced its Merck position by 16.7% in the third quarter, selling 13,754 shares and retaining 68,478 shares valued at approximately $9.95 million. Institutional investors collectively own 76.07% of MRK.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $151.92; recent target increases ranged from $145 to $170.
• Merck reported quarterly revenue of $16.61 billion, up 5.1% year over year, and beat EPS expectations. The company also paid a quarterly dividend of $0.85 per share, representing a 2.3% annualized yield, while insiders sold significant amounts of stock over the past 90 days.

1834 Investment Advisors Co. decreased its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 16.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 68,478 shares of the company's stock after selling 13,754 shares during the period. Merck & Co., Inc. comprises approximately 0.9% of 1834 Investment Advisors Co.'s portfolio, making the stock its 26th biggest holding. 1834 Investment Advisors Co.'s holdings in Merck & Co., Inc. were worth $9,951,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of MRK. Round Rock Advisors LLC raised its stake in shares of Merck & Co., Inc. by 0.7% during the 2nd quarter. Round Rock Advisors LLC now owns 9,901 shares of the company's stock worth $1,272,000 after buying an additional 66 shares during the last quarter. Cascade Financial Partners LLC boosted its position in shares of Merck & Co., Inc. by 0.5% in the 2nd quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company's stock worth $1,895,000 after buying an additional 80 shares in the last quarter. Somerset Trust Co grew its stake in Merck & Co., Inc. by 0.9% in the 2nd quarter. Somerset Trust Co now owns 8,701 shares of the company's stock valued at $1,118,000 after acquiring an additional 81 shares during the last quarter. Stonebridge Financial Group LLC grew its stake in Merck & Co., Inc. by 0.9% in the 2nd quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company's stock valued at $1,124,000 after acquiring an additional 81 shares during the last quarter. Finally, Stronghold Wealth Management L.L.C. increased its holdings in Merck & Co., Inc. by 2.6% during the 2nd quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company's stock valued at $416,000 after acquiring an additional 82 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on MRK shares. Cantor Fitzgerald lifted their target price on shares of Merck & Co., Inc. from $120.00 to $145.00 and gave the stock a "neutral" rating in a research report on Thursday, October 8th. Barclays upped their price target on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the company an "overweight" rating in a report on Wednesday, July 29th. JPMorgan Chase & Co. increased their price target on shares of Merck & Co., Inc. from $150.00 to $165.00 and gave the company an "overweight" rating in a research report on Monday, October 5th. Guggenheim raised their price objective on shares of Merck & Co., Inc. from $146.00 to $170.00 and gave the stock a "buy" rating in a research note on Tuesday, September 8th. Finally, Wall Street Zen downgraded Merck & Co., Inc. from a "buy" rating to a "hold" rating in a research report on Saturday, October 3rd. Seventeen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $151.92.

Merck & Co., Inc. Trading Up 0.6%

Shares of MRK stock opened at $146.01 on Friday. The firm has a 50-day moving average price of $145.60 and a 200 day moving average price of $129.24. Merck & Co., Inc. has a twelve month low of $82.01 and a twelve month high of $156.92. The company has a market capitalization of $360.22 billion, a price-to-earnings ratio of 116.81, a PEG ratio of 6.74 and a beta of 0.21. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same period in the prior year, the firm earned $2.13 EPS. The firm's quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Research analysts forecast that Merck & Co., Inc. will post 2.66 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were paid a dividend of $0.85 per share. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. Merck & Co., Inc.'s dividend payout ratio is presently 272.00%.

Insider Activity

In related news, EVP Chirfi Guindo sold 10,000 shares of the firm's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the sale, the executive vice president owned 36,613 shares in the company, valued at approximately $4,942,755. This trade represents a 21.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Maraldo sold 18,706 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the sale, the executive vice president directly owned 18,212 shares of the company's stock, valued at $2,344,248.64. The trade was a 50.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 228,238 shares of company stock valued at $29,977,783 in the last 90 days. Insiders own 0.17% of the company's stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported promising skin-cancer trial results involving Keytruda and a personalized mRNA vaccine. Positive clinical data could strengthen confidence in Merck’s oncology franchise and support longer-term growth. Merck reports promising skin cancer trial results
• Positive Sentiment: Merck is scheduled to present first-time pivotal Phase 3 oncology results at ESMO 2026, including melanoma and endometrial-cancer programs, alongside an oncology investor event. The disclosures may demonstrate progress in replacing or extending revenue from existing cancer therapies. Merck ESMO 2026 oncology pipeline preview
• Positive Sentiment: Merck’s continued uptrend has encouraged options traders to consider bullish strategies, indicating that some market participants expect further gains. Options activity, however, can amplify volatility and does not by itself change the company’s fundamentals. Merck bullish options strategy
• Neutral Sentiment: Merck’s investment narrative has shifted toward oncology and other growth opportunities as investors look beyond challenges affecting Gardasil, particularly in China. The strategy could improve diversification, but execution and pipeline commercialization remain key.
• Neutral Sentiment: Merck is being compared favorably with other pharmaceutical companies on dividend sustainability and cash generation, though the articles do not identify a major new dividend announcement. Merck versus Amgen dividend comparison
• Negative Sentiment: After rising more than 38% in 2026, Merck trades at a substantially higher forward earnings multiple than in late 2025. Analysts warn that the market may already be pricing in significant pipeline success, leaving less room for upside and greater sensitivity to disappointing trial data. Merck valuation and rally analysis

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck's principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.